Anavex Life Sciences Corp (AVXL)

[nidan7500]

blue. I completely agree with your message.

Anavex has fits with what Gottlieb wants for his new FDA,and that`s a major focus on CNS diseases. Anavex is perfectly timed for this union between what Anavex has and what the FDA wants to see happen in the CNS disease arena. Talk about being in the sweet spot.

.

As far as we know A2-73 pts in this test are remaining in the study, w/dose as controlled. Contrast that with ALL PREVIOUS AD studies (99.6%) failure rate. IMO, the FDA could be justified in declaring a victory based on A2-73 results to date and additional information which we have not seen. If every other test has always failed then why is NOT FAIL not a win? Retained or improved cognitive skills has never happened in such trials. This is up to the FDA to consider. As Falconer's reported research indicates there has been no published contradiction to CNS Homeostasis potential impact.

Also, since no studies/trials have ever got to this point what else is being learned that has never previously been understood? Very smart/capable people are (IMO) pushing through the interface(depletion region) between what they knew they did not know and what they did not know they did not know. At this point the best that can be said (if A2-73 is effective) is that patients look, act, and think/feel better. The quality of their lives is being restored, but we have no idea/cannot explain why just yet.